3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Unspecified Adult Solid Tumor, Protocol Specific
5
Prostatic Neoplasms
4
Multiple Myeloma
4
Lymphoma, Mantle-Cell
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia
4
Hodgkin Disease
4
Carcinoma, Non-Small-Cell Lung
4
Lymphoma, Non-Hodgkin
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Lung Neoplasms
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Accelerated Phase
3
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Burkitt Lymphoma
3
Blast Crisis
3
Sezary Syndrome
2
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Mycosis Fungoides
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Anaplastic
2
Interventions
Brentuximab Vedotin
17
fludarabine
9
Cyclophosphamide
9
dacetuzumab
6
Lenalidomide
6
Bortezomib
6
ruxolitinib
5
fludarabine phosphate
5
Rituximab
5
Melphalan
5
Dexamethasone
4
Busulfan
4
lintuzumab
3
Whole-Body Irradiation
3
Mycophenolic Acid
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Doxorubicin
3
Calcium Dobesilate
3
Azacitidine
3
vosaroxin
2
spartalizumab
2
ponatinib
2
nilotinib
2
Vincristine
2
Thiotepa
2
Tacrolimus
2
Sugars
2
Stem Cell Transplantation
2
Rifampin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hematologic Diseases
×
tanespimycin
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled